Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire

Journal of Neurogastroenterology and Motility

Volumn 19, Issue 1, 2013, Pages 61-69

  Jo, So Young ^a   Kim, Nayoung ^a,b   Lim, Ji Hwan ^a   Shin, Cheol Min ^a   Park, Young Soo ^a,b   Lee, Dong Ho ^a,b   Jung, Hyun Chae ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Functional heartburn; Gastroesophageal reflux; Proton pump inhibitors; Quality of life; Questionnaires

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; EATING DISORDER; ENDOSCOPY; EPIGASTRIC PAIN; ESOPHAGUS PH; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROESOPHAGEAL REFLUX DISEASE IMPACT SCALE QUESTIONNAIRE; HEARTBURN; HIATUS HERNIA; HOARSENESS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON EROSIVE REFLUX DISEASE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RISK ASSESSMENT; SLEEP DISORDER; SMOKING; SYMPTOM; THORAX PAIN; TREATMENT RESPONSE;

EID: 84876718702     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2013.19.1.61     Document Type: Article

References (45)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
2. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996;276: 983-988.
3. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):24-29.
4. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-180.
5. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
6. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA. Functional esophageal disorders. Gut 1999;45(suppl 2):II31-II36.
7. Galmiche JP, Clouse RE, Bálint A, et al. Functional esophageal disorders. Gastroenterology 2006;130:1459-1465.
8. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108-114.
9. Wiklund I, Talley NJ. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoecon Outcomes Res 2003;3:341-350.
10. Prasad M, Rentz AM, Revicki DA. The impact of treatment for gastro- oesophageal reflux disease on health-related quality of life: a literature review. Pharmacoeconomics 2003;21:769-790.
11. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-57.
12. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009;30:1030- 1038.
13. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998;7:75-83.
14. Jones R, Coyne K, Wiklund I. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007;25:1451-1459.
15. Lee E, Kim N, Lee S, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non erosive reflux disease. Aliment Pharmacol Ther 2009; 30:154-164.
16. Wong WM, Lai KC, Lam KF, et al. Onset and disappearance of reflux symptoms in a Chinese population: a 1 year follow up study. Aliment Pharmacol Ther 2004;20:803-812.
17. van Zanten SV, Wahlqvist P, Talley NJ, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study. Aliment Pharmacol Ther 2011;34:714-723.
18. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-124.
19. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995;90:1053-1057.
20. Lee KJ, Kwon HC, Chng JY, Cho SW. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group. Digestion 2009;79:131-136.
21. Bolling-Sternevald E, Carlsson R, Aalykke C, et al. Self-administered symptom questionnaires in patients with dyspepsia and their yield in discriminating between endoscopic diagnoses. Dig Dis 2000;20:191-198.
22. Welén K, Faresjö A, Faresjö T. Functional dyspepsia affects women more than men in daily life: a case-control study in primary care. Gend Med 2008;5:62-73.
23. Flier SN, Rose S. Is functional dyspepsia of particular concern in women"; a review of gender differences in epidemiology, pathophysiologic mechanisms, clinical presentation, and management. Am J Gastroenterol 2006;101(12 suppl):S644-S653.
24. Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity, and gastroesophageal reflux symptoms. Gut 2007;56:756-762.
25. Lee HL, Eun CS, Lee OY, et al. Association between GERD-related erosive esophagitis and obesity. J Clin Gastroenterol 2008;42: 672-675.
26. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999;94:2840-2844.
27. Johnston BT, Lewis SA, Collins JS, McFarland RJ, Love AH. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995;30:1-5.
28. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995;37:7-12.
29. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-1656.
30. Sarnelli G, De Giorgi F, Efficie E, et al. Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease. Eur J Gastroenterol Hepatol 2008;20:264- 268.
31. Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009;58:1185-1191.
32. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-1029.
33. Manterola C, Muñoz S, Grande L, Bustos L. Initial validation of a questionnaire for detecting gastroesophageal reflux disease in epidemiological settings. J Clin Epidemiol 2002;55:1041-1045.
34. Kim N, Lee SW, Cho SI, et al. The prevalence and risk factors of erosive oesophagitis and non-erosive reflux disease: a nationwide multi-centre prospective study in Korea. Aliment Pharmacol Ther 2008;27:173-185.
35. Schey R, Dickman R, Parthasarathy S, et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology 2007;133:1787-1795.
36. Jung HK, Choung RS, Talley NJ. Gastroesophageal reflux disease and sleep disorders: Evidence for a causal link and therapeutic implications. J Neurogastroenterol Motil 2010;16:22-29.
37. Orr WC, Goodrich S, Fernström P, Hasselgren G. Occurrence of nighttime gastroesophageal reflux in disturbed and normal sleepers. Clin Gastroenterol Hepatol 2008;6:1099-1104.
38. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100: 1914-1922.
39. Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment Pharmacol Ther 2005;21:103-108.
40. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005;18:370-373.
41. Robinson M, Rodriguez-Stanley S, Ciociola AA, et al. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig Dis Sci 2002;47:265-273.
42. McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: how well do clinician's assessments agree with those of their patients? Am J Gastroenterol 2005;100:11-18.
43. Masanori H, Kazunori M, Hiroshi Y, et al. Esophageal motility and psychiatric fctors in functional dyspepsia patients with or without pain. Dig Dis Sci 1999;44:2094-2098.
44. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, plac-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
45. Schey R, Shapiro M, Navarro-Rodriguez T, et al. Comparison of the different characteristics of sensed reflux events among different heartburn groups. J Clin Gastroenterol 2009;43:699-704.